GI
BIOA

GAMMA Investing’s BioAge Labs BIOA Stock Holding History

GAMMA Investing’s Portfolio BIOA Stock Details BIOA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$221 Sell
9
-28
-76% -$506 ﹤0.01% 4082
2026
Q1 		$647 Buy
+37
New +$713 ﹤0.01% 3910

Other funds holding BIOA

MAP
Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
TM
Torren Management San Diego, California $197M AUM
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.87B AUM 24.64% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return

GAMMA Investing's BIOA Position: Q2 2026 in Review

GAMMA Investing reduced its BioAge Labs (BIOA) stake by 76% in Q2 2026, selling an estimated $506 and leaving 9 shares worth $221. The position accounts for ﹤0.01% of the portfolio, ranked #4082.

GAMMA Investing first reported a position in BIOA in Q1 2026 and has held it in 2 quarters since. The position peaked at $647 in Q1 2026. 7 funds tracked by Wall St. Rank hold BIOA as of Q2 2026.

  • GAMMA Investing held 9 shares of BioAge Labs worth $221 as of Q2 2026.
  • GAMMA Investing sold 28 BioAge Labs shares in Q2 2026, an estimated $506.
  • BioAge Labs made up ﹤0.01% of GAMMA Investing's portfolio in Q2 2026, its #4082 holding.
  • GAMMA Investing first reported a position in BioAge Labs in Q1 2026 and has held it in 2 quarters since.
  • GAMMA Investing's BioAge Labs position peaked at $647 in Q1 2026.
  • 7 funds tracked by Wall St. Rank held BioAge Labs as of Q2 2026.

Based on GAMMA Investing's 13F filing for Q2 2026, filed 7 Jul 2026.